EA201001332A1 - Соединения и композиции в качестве модуляторов активности gpr119 - Google Patents
Соединения и композиции в качестве модуляторов активности gpr119Info
- Publication number
- EA201001332A1 EA201001332A1 EA201001332A EA201001332A EA201001332A1 EA 201001332 A1 EA201001332 A1 EA 201001332A1 EA 201001332 A EA201001332 A EA 201001332A EA 201001332 A EA201001332 A EA 201001332A EA 201001332 A1 EA201001332 A1 EA 201001332A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- compositions
- gpr119 activity
- activity modulators
- gpr119
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
В заявке описаны соединения, фармацевтические композиции, содержащие такие соединения, и способы применения таких соединений для лечения или предупреждения заболеваний или нарушений, связанных с активностью GPR119.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3090708P | 2008-02-22 | 2008-02-22 | |
PCT/US2009/034781 WO2009105715A1 (en) | 2008-02-22 | 2009-02-20 | Compounds and compositions as modulators of gpr119 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201001332A1 true EA201001332A1 (ru) | 2011-04-29 |
Family
ID=40512579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201001332A EA201001332A1 (ru) | 2008-02-22 | 2009-02-20 | Соединения и композиции в качестве модуляторов активности gpr119 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110166176A1 (ru) |
EP (1) | EP2262496A1 (ru) |
JP (1) | JP2011513232A (ru) |
KR (1) | KR20100120689A (ru) |
CN (1) | CN102006870A (ru) |
AU (1) | AU2009217359B2 (ru) |
BR (1) | BRPI0907584A2 (ru) |
CA (1) | CA2714703A1 (ru) |
EA (1) | EA201001332A1 (ru) |
MX (1) | MX2010009204A (ru) |
WO (1) | WO2009105715A1 (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5467151B2 (ja) | 2009-06-24 | 2014-04-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
AR077214A1 (es) | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2015522080A (ja) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 |
US9169205B2 (en) | 2012-10-08 | 2015-10-27 | Boehringer Ingelheim International Gmbh | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
WO2014114578A1 (en) * | 2013-01-25 | 2014-07-31 | Boehringer Ingelheim International Gmbh | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
US8962641B2 (en) * | 2013-04-17 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
JP6378752B2 (ja) * | 2013-05-17 | 2018-08-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピロリジン誘導体、その医薬組成物及び使用 |
CN104892517A (zh) * | 2015-02-13 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | 酰肼类化合物、其制备方法及用途 |
CN104592120A (zh) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途 |
CN104610151A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 含酰肼和烷氧苯类结构的化合物、其制备方法及用途 |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
DE602005011279D1 (de) * | 2004-06-04 | 2009-01-08 | Arena Pharm Inc | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen |
DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
AU2006264651A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
JP2008545008A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
-
2009
- 2009-02-20 JP JP2010547819A patent/JP2011513232A/ja active Pending
- 2009-02-20 KR KR1020107021109A patent/KR20100120689A/ko not_active Application Discontinuation
- 2009-02-20 AU AU2009217359A patent/AU2009217359B2/en not_active Ceased
- 2009-02-20 MX MX2010009204A patent/MX2010009204A/es not_active Application Discontinuation
- 2009-02-20 EP EP09711737A patent/EP2262496A1/en not_active Withdrawn
- 2009-02-20 CA CA2714703A patent/CA2714703A1/en not_active Abandoned
- 2009-02-20 BR BRPI0907584-4A patent/BRPI0907584A2/pt not_active IP Right Cessation
- 2009-02-20 WO PCT/US2009/034781 patent/WO2009105715A1/en active Application Filing
- 2009-02-20 CN CN200980113843XA patent/CN102006870A/zh active Pending
- 2009-02-20 US US12/918,805 patent/US20110166176A1/en not_active Abandoned
- 2009-02-20 EA EA201001332A patent/EA201001332A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
US20110166176A1 (en) | 2011-07-07 |
AU2009217359B2 (en) | 2011-09-01 |
MX2010009204A (es) | 2010-11-10 |
JP2011513232A (ja) | 2011-04-28 |
EP2262496A1 (en) | 2010-12-22 |
WO2009105715A1 (en) | 2009-08-27 |
KR20100120689A (ko) | 2010-11-16 |
CA2714703A1 (en) | 2009-08-27 |
BRPI0907584A2 (pt) | 2015-07-21 |
AU2009217359A1 (en) | 2009-08-27 |
CN102006870A (zh) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA200901157A1 (ru) | Конденсированные кольцевые гетероциклические модуляторы киназы | |
EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
EA201170349A1 (ru) | Модуляторы mif | |
EA201071089A1 (ru) | Производные хиназолина как модуляторы raf-киназы и способы их применения | |
EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
EA201790267A1 (ru) | Новые модуляторы киназ | |
EA201001331A1 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR | |
EA201001639A1 (ru) | Композиции и способы их получения и применения | |
TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
TW200801021A (en) | Imidazolothiazole compounds for the treatment of disease | |
EA200971077A1 (ru) | Гетероциклические модуляторы киназы | |
MX2012002066A (es) | Compuestos heterociclicos y usos de los mismos. | |
IN2012DN00943A (ru) | ||
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
EA200602242A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. |